BAT2020 / Bio-Thera Solutions - LARVOL DELTA

A Phase 1/2 Study to Assess Safety and Efficacy of BAT2020 in Hospitalized COVID-19 Patients (clinicaltrials.gov) - P1/2; N=0; Withdrawn; Sponsor: Bio-Thera Solutions; N=174 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase 1/2 Study to Assess Safety and Efficacy of BAT2020 in Hospitalized COVID-19 Patients (clinicaltrials.gov) - P1/2; N=174; Not yet recruiting; Sponsor: Bio-Thera Solutions; Phase classification: P1 ➔ P1/2; Trial completion date: Jan 2021 ➔ Aug 2021; Initiation date: Jul 2020 ➔ Oct 2020; Trial primary completion date: Oct 2020 ➔ Jan 2021

Clinical • Phase classification • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

A Phase 1 Study to Assess BAT2020 in Hospitalized Patients Infected With SARS-CoV-2 (COVID-19) (clinicaltrials.gov) - P1; N=174; Not yet recruiting; Sponsor: Bio-Thera Solutions

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease